Microspheres based on inulin for the controlled release of serine protease inhibitors: preparation, characterization and in vitro release.

[1]  Sidney Addelman,et al.  trans-Dimethanolbis(1,1,1-trifluoro-5,5-dimethylhexane-2,4-dionato)zinc(II) , 2008, Acta crystallographica. Section E, Structure reports online.

[2]  J. Jay,et al.  Microencapsulation par évaporation de solvant , 2001 .

[3]  I. Enyedy,et al.  Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. , 2001, Journal of medicinal chemistry.

[4]  P. Lam,et al.  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.

[5]  X. Wu,et al.  Preparation and characterization of inulin ester microspheres as drug carriers , 2000 .

[6]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[7]  M. Whitlow,et al.  Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors. , 1999, Journal of medicinal chemistry.

[8]  R. Bartus,et al.  Cereport™ (RMP-7) Increases the Permeability of Human Brain Microvascular Endothelial Cell Monolayers1 , 1999, Pharmaceutical Research.

[9]  E. Mackenzie,et al.  Transforming growth factor‐βl as a regulator of the serpins/t‐PA axis in cerebral ischemia , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  J. Irache,et al.  Gliadin nanoparticles: formation, all- trans-retinoic acid entrapment and release, size optimization , 1999 .

[11]  L. Vervoort,et al.  Inulin hydrogels as carriers for colonic drug targeting. Rheological characterization of the hydrogel formation and the hydrogel network. , 1999, Journal of pharmaceutical sciences.

[12]  R. Huber,et al.  Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. , 1998, Journal of medicinal chemistry.

[13]  Joop A. Peters,et al.  Modification of inulin with amidoxime groups and coordination with copper(II) ions , 1998 .

[14]  C. Chu,et al.  Inulin polysaccharide having pendant amino acids: Synthesis and characterization , 1998 .

[15]  M. Whitlow,et al.  Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. , 1998, Journal of medicinal chemistry.

[16]  M. Morrissey,et al.  (Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa. , 1998, Journal of medicinal chemistry.

[17]  S. Rabbani,et al.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.

[18]  M. Gohel,et al.  Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[20]  Y. Sugiyama,et al.  Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: in vivo evidence by use of the brain efflux index method. , 1997, The Journal of pharmacology and experimental therapeutics.

[21]  P. Carmeliet,et al.  Molecular analysis of blood vessel formation and disease. , 1997, American journal of physiology. Heart and circulatory physiology.

[22]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[23]  S. Hanson,et al.  Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation , 1997, Thrombosis and Haemostasis.

[24]  P. Carmeliet,et al.  Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. , 1997, Current opinion in lipidology.

[25]  H. Fessi,et al.  Preparation of pseudolatex by nanoprecipitation: Influence of the solvent nature on intrinsic viscosity and interaction constant , 1997 .

[26]  S. Tsirka,et al.  Neuronal cell death and tPA , 1996, Nature.

[27]  M. Llinás,et al.  Complexation of the tissue plasminogen activator protease with benzamidine-type inhibitors: interference by the kringle 2 module. , 1996, Biochemistry.

[28]  A. Gustavo González,et al.  Optimization of pharmaceutical formulations based on response-surface experimental designs , 1993 .

[29]  P. Cooper,et al.  The adjuvanticity of gamma inulin , 1988, Immunology and cell biology.

[30]  H. Vieweg,et al.  [Synthesis of alpha-alpha'-Bis-[amidinobenzylides]-and alpha-alpha'-Bis-[amidinobenzyl]-cycloalkanones]. , 1977, Die Pharmazie.

[31]  L. Barré,et al.  Total synthesis and radiolabelling of an efficient rt-PA inhibitor: [11C] (Z,Z)-BABCH. A first route to [11C] labelled amidines , 2001 .

[32]  Françoise Candau,et al.  Biopolymer and polymer nanoparticles and their biomedical applications , 2000 .

[33]  Hari Singh Nalwa,et al.  Handbook of nanostructured materials and nanotechnology , 2000 .

[34]  M. Roberfroid,et al.  Nutritional and Health Benefits of Inulin and Oligofructose Concepts in Functional Foods: The Case of Inulin and Oligofructose 1 , 1999 .

[35]  P. Coussement.  Nutritional and Health Benefits of Inulin and Oligofructose Inulin and Oligofructose: Safe Intakes and Legal Status 1 , 1999 .

[36]  L. Prockop,et al.  Entry rate kinetics of D-mannitol and carboxyl-inulin for transfer across the blood-cerebrospinal fluid barrier. , 1997, The journal of spinal cord medicine.

[37]  K. Matsumoto,et al.  Production of Fructo-Oligosaccharide-Rich Fructose Syrup , 1993 .

[38]  A. Fuchs,et al.  Inulin and inulin-containing crops. , 1993 .

[39]  L. Molteni.  [22] Dextran and inulin conjugates as drug carriers , 1985 .

[40]  G. Wagner.  Synthesis of benzamidine derivatives as inhibitors of clotting enzymes. , 1982, Folia haematologica.